Rapport Therapeutics (NASDAQ:RAPP) Research Coverage Started at TD Cowen

Equities researchers at TD Cowen began coverage on shares of Rapport Therapeutics (NASDAQ:RAPP) in a report issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating on the stock.

A number of other research analysts have also recently weighed in on the stock. Stifel Nicolaus began coverage on shares of Rapport Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 price target on the stock. Jefferies Financial Group began coverage on shares of Rapport Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 price target on the stock.

Rapport Therapeutics Trading Down 6.8 %

RAPP opened at $23.30 on Tuesday. Rapport Therapeutics has a 1 year low of $18.00 and a 1 year high of $27.11.

Insider Activity

In other news, Director James Healy acquired 44,032 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were bought at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the completion of the purchase, the director now directly owns 40,851 shares of the company’s stock, valued at approximately $1,001,666.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.